Daiichi Sankyo, ArQule Colorectal Cancer Drug Fails Phase II Trial
This article was originally published in PharmAsia News
Daiichi Sankyo's colorectal cancer drug tivatinib co-developed with U.S.-based ArQule, failed a Phase II clinical trial testing improvements of survival and improved response, the companies reported.
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.